Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Immunol ; 176: 63-70, 2017 03.
Article in English | MEDLINE | ID: mdl-28025135

ABSTRACT

Cancer is currently treated by a combination of therapies, including chemotherapy which is believed to suppress the immune system. Combination of immunotherapy and chemotherapy correlates with improved survival but needs careful planning in order to achieve a synergistic effect. In this study, we have demonstrated that doxorubicin treatment of B cells resulted in increased expression of CD86 and concordantly increased CD4+ T cell activation in the presence of superantigen, an effect that was inhibited by the addition of a CD86 blocking antibody. Furthermore, doxorubicin resulted in decreased expression of the anti-inflammatory cytokines IL-10 and TNF-α. Finally, B cells from urinary bladder cancer patients, treated with a neoadjuvant regiment containing doxorubicin, displayed increased CD86-expression. We conclude that doxorubicin induces CD86 expression on B cells and hence enhances their antigen-presenting ability in vitro, a finding verified in patients. Development of tailored time and dose schedules may increase the effectiveness of combining chemotherapy and immunotherapy.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/immunology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , B-Lymphocytes/drug effects , CD4-Positive T-Lymphocytes/drug effects , Lymphocyte Activation/drug effects , Urinary Bladder Neoplasms/drug therapy , Urinary Bladder Neoplasms/therapy , Aged , Aged, 80 and over , Antigen Presentation/drug effects , Antigen Presentation/immunology , Antigen-Presenting Cells/drug effects , Antigen-Presenting Cells/immunology , B-Lymphocytes/immunology , B7-2 Antigen/immunology , CD4-Positive T-Lymphocytes/immunology , Doxorubicin/administration & dosage , Female , Humans , Immunotherapy/methods , Interleukin-10/immunology , Lymphocyte Activation/immunology , Male , Middle Aged , Tumor Necrosis Factor-alpha/immunology , Urinary Bladder Neoplasms/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...